Opaleye Management Inc. Kiniksa Pharmaceuticals, Ltd. Transaction History

Opaleye Management Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$14.37 - $19.07 $538,875 - $715,125	37,500 New	37,500 $657,000
Q2 2022 Aug 15, 2022	SELL	$7.6 - $11.41 $2.27 Million - $3.4 Million	-298,250 Reduced 26.81%	814,250 $7.89 Million
Q1 2022 May 16, 2022	BUY	$9.3 - $12.37 $813,750 - $1.08 Million	87,500 Added 8.54%	1,112,500 $11.1 Million
Q4 2021 Feb 14, 2022	SELL	$10.39 - $15.15 $2.96 Million - $4.32 Million	-285,000 Reduced 21.76%	1,025,000 $12.1 Million
Q3 2021 Nov 16, 2021	BUY	$11.39 - $16.23 $1.76 Million - $2.51 Million	154,800 Added 13.4%	1,310,000 $14.9 Million
Q2 2021 Aug 16, 2021	BUY	$13.22 - $19.09 $11 Million - $15.9 Million	834,274 Added 259.96%	1,155,200 $16.1 Million
Q1 2021 May 18, 2021	BUY	$16.68 - $23.97 $1.62 Million - $2.32 Million	96,826 Added 43.21%	320,926 $5.94 Million
Q4 2020 Feb 12, 2021	SELL	$14.8 - $21.15 $1.69 Million - $2.41 Million	-113,900 Reduced 33.7%	224,100 $3.96 Million
Q3 2020 Nov 16, 2020	SELL	$15.21 - $25.53 $98,865 - $165,945	-6,500 Reduced 1.89%	338,000 $8.78 Million
Q2 2020 Aug 14, 2020	BUY	$15.08 - $26.0 $5.2 Million - $8.96 Million	344,500 New	344,500 $8.78 Million

1.95M

Ticker KNSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,470,400
Market Cap $687M
Description
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.